Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• The (never in mitosis gene A)-related kinase 2 (NEK2) is upregulated in multiple myeloma (MM), contributing to drug resistance.
• Mechanisms driving NEK2 upregulation in MM are not fully understood.

Purpose of the Study:

• Investigate the mechanisms of NEK2 upregulation in MM.
• Determine the role of NEK2 and TP53 in MM progression and drug resistance.
• Evaluate NEK2 as a potential therapeutic target in MM.

Main Methods:

• Analysis of NEK2 amplification and promoter methylation in MM.
• In vitro and in vivo studies using MM cell lines with varying TP53 and NEK2 status.
• Assessment of tumor formation, drug resistance, and therapeutic responses.

Main Results:

• NEK2 amplification and promoter hypermethylation correlate with increased NEK2 expression in MM.
• NEK2 amplification and TP53 deletion are associated with poor survival in MM patients.
• Combined TP53 loss and NEK2 overexpression promote MM aggressiveness, drug resistance, and tumorigenesis.
• Restoring p53 and suppressing NEK2 inhibits tumor growth and enhances bortezomib efficacy in TP53-deficient MM cells.
• Inactivating p53 upregulates NEK2 via genetic amplification, transcriptional activation, and epigenetic modifications.

Conclusions:

• Dual defects in TP53 and NEK2 identify a high-risk MM subgroup.
• NEK2 is a key driver of MM aggressiveness and drug resistance, particularly in the context of p53 inactivation.
• NEK2 represents a promising therapeutic target for aggressive MM with p53 abnormalities.